MGMT and central nervous system cancer: Molecular alterations in gliomas have diagnostic, predictive, and prognostic value critical for effective treatment selection, e.g., the presence of MGMT promoter methylation was associated with a beneficial sensitivity to alkylating agent chemotherapy, resulting in prolonged survival in glioblastoma patients2,5.